Prof. Alessandro Armuzzi leads the Inflammatory Bowel Disease (IBD) Unit and co-leads the IBD Center at the IRCCS Humanitas Research Hospital, Milan, Italy. He is also full Professor of Gastroenterology and Director of the Gastroenterology Residency Program at Humanitas University, Milan, Italy.
Professor Armuzzi trained at the University of Bologna, Catholic University of Rome, and completed advanced research and clinical training in IBD at the John Radcliffe Hospital, Oxford University Hospitals, UK.
Professor Armuzzi’s research interests focus on the design of both real-life trials and observational studies in IBD, clinical/biological prediction and outcomes in IBD and other immune-mediated diseases, diagnostic modalities to assess disease activity in IBD, and advanced IBD therapies.
He is the Author of more than 390 scientific papers published in peer-reviewed impact-factored scientific journals with a personal impact factor of more than 3.500, a Scopus H-index of 62 and more than 17,000 citations.
Professor Armuzzi served as a member of several gastroenterology associations, including the Scientific Committee of the Italian Society of Gastroenterology (SIGE, Scientific Committee 2014-2017), the Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD, Chair from 2018 to 2019, EduCom Chair 2020-2021, 2024) and has fulfilled multiple roles within the European Crohn’s and Colitis Organisation (ECCO) including Chair of the Clinical Research Committee (ClinCom) between 2015 and 2017, Internal Auditor between 2019 and 2020, and General Secretary between 2021 and 2024.
Selected publications from PubMed
Ustekinumab and Janus Kinase Inhibitors Outperform Vedolizumab as Second-Line Therapy in Anti-Tumor Necrosis Factor-Experienced Patients With Ulcerative Colitis.
Privitera G, Bezzio C, Figlioli G, D'Amico F, Mendes J, Varca S, Zingone F, Rodriguez-Lago I, Onali S, Caprioli FA, Chaparro M, Barreiro-de-Acosta M, Karmiris K, Degabli NT, Dar L, Pastorelli L, Gutiérrez A, Orlando A, Zabana Y, Saibeni S, Piovani D, Savarino EV, Pugliese D, Magro F, Danese S, Armuzzi A, PODIUM Study Group
Clin Gastroenterol Hepatol. 2026 Sep;24(9):2539-2550 doi: 10.1016/j.cgh.2026.01.017.
Clinical Outcomes After Ustekinumab Biosimilar Switching in Crohn's Disease: The USBIOS-Italian Group for the Study of Inflammatory Bowel Disease Study.
Ribaldone DG, Tribocco E, Scaldaferri F, Murgiano M, Parello S, Di Vincenzo F, Del Gaudio A, Puca P, Napolitano D, Papa A, Lopetuso LR, Laterza L, Bezzio C, Armuzzi A, Farinola V, Savarino EV, Zingone F, Barberio B, Bertin L, Todeschini A, Variola A, Carvalhas Gabrielli AM, Ferretti F, Cannatelli R, Gravina AG, Pellegrino R, Viola A, De Francesco C, Bossa F, Pastorelli L, Felice C, Dragoni G, Canova D, Cingolani L, Spagnuolo R, Terpin MM, Zilli A, Magiotta A, Segatta F, Saibeni S, Juverdeanu A, Vernero M, Caviglia GP
Clin Gastroenterol Hepatol. 2026 Aug 27 pii: S1542-3565(26)00637-3. doi: 10.1016/j.cgh.2026.08.014.
Arthritis in inflammatory bowel disease.
Bartoloni E, Caprioli F, Armuzzi A, Perricone C, Cafaro G, Orlando A, Fantini MC, Gerli R
Rheumatology (Oxford). 2026 Aug 13 pii: keag422. doi: 10.1093/rheumatology/keag422.
Positioning Guselkumab in The Treatment Algorithm for Ulcerative Colitis.
D'Amico F, Fanizzi F, Magro F, Dignass A, Gutiérrez Casbas A, Verstockt B, Hart A, Armuzzi A, Jairath V, Peyrin-Biroulet L, Danese S
J Inflamm Res. 2026;19:546273 doi: 10.2147/JIR.S546273.
Comparative risk of postoperative complications in ulcerative colitis patients following preoperative advanced therapies: a network meta-analysis with meta-regression.
Hayek MA, Estevinho MM, Kayal M, Hayek OA, Armuzzi A, Burisch J, Najah Q, Jairath V, Wexner SD, Loftus EV Jr, Peyrin-Biroulet L, Danese S, Elhadi M, Magro F
J Crohns Colitis. 2026 Aug 5;20(8) pii: jjag111. doi: 10.1093/ecco-jcc/jjag111.
Help your network discover Prof. Alessandro Armuzzi's clinical expertise.
